HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Exclusion Criteria

• •1. Distal cholangiocarcinoma.
• •2. Allergic to contrast agent.
• •3. Pregnant or lactational.
• •4. Allergic to 5-fluorouracil, or have metabolic disorder of 5-fluorouracil.
• •5. More than 80 years old.
• •6. Previous systematic chemotherapy or radiotherapy.
• •7. Child-Pugh C or Child-Pugh B (≥ score 8).
• •8. Coinstantaneous a lot of malignant hydrothorax or ascites.
• •9. History of organ transplantation (including bone marrow auto-transplantation and peripheral stem cell transplantation).
• •10. Coinstantaneous infection and need anti-infection therapy.
• •11. Hepatitis B virus DNA load ≥ 100 IU/ml (patients whose hepatitis B virus DNA load decreased to \< 100 IU/ml after anti-virus therapy could be enrolled).
• •12. Coinstantaneous peripheral nervous system disorder or with history of obvious mental disorder and central nervous system disorder.
• •13. Diagnosed other kinds of malignant within 5 years, except for non-melanoma skin cancer and carcinoma in situ of cervix.
• •14. Without legal capacity.
• •15. Impact the study because of medical or ethical reasons.
• •16. Uncorrectable coagulation disorder.
• •17. Obvious abnormal in ECG or obvious clinical symptoms of heart disease, like congestive heart failure (CHF), coronary heart disease with obvious clinical symptoms, unmanageable arrhythmia and hypertension.
• •18. History of myocardial infarction within 12 months, or Grade III/IV of heart function.
• •19. Severe liver disease (like cirrhosis), renal disease, respiratory disease, unmanageable diabetes or other kinds of systematic disease.